1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Bioengineering Partnerships with Industry (BPI) is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at NIH that supports interdisciplinary, multi-institutional research partnerships between academic investigators and industry partners to solve significant biomedical engineering problems.
The BPI program recognizes that translating biomedical innovations into practical health solutions requires collaboration between universities and the private sector, combining each group's unique strengths in basic research and applied development. Priority areas include image-guided interventions and other bioengineering challenges where industry engagement accelerates clinical impact.
Eligible applicants are research partnerships formed by academic and industrial investigators. Grant amounts are not specified and vary by project scope and partnership structure.
Get alerted about grants like this
Save a search for “National Institute of Biomedical Imaging and Bioengineering (NIBIB) / NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Bioengineering Partnerships with Industry (BPI) | National Institute of Biomedical Imaging and Bioengineering Bioengineering Partnerships with Industry (BPI) Division of Applied Science & Technology (Biomedical Imaging) Program Area: Image-Guided Interventions Program Announcement: PAR-24-325 For many years, the NIH has recognized that the application of principles and techniques from physics, mathematics, chemistry, computer sciences, and engineering can be used to solve significant biomedical problems, leading in turn to new understanding of biological processes, novel products, and innovative tools to improve health.
Such solutions typically require inter-disciplinary, multi-institutional partnerships to combine strengths unique to each group. Moreover, it is essential to engage industry for the eventual broader application and adoption of the technologies and tools to realize the full potential and bring the benefits of these technological innovations to patients.
The academic-industrial partnership model is expected to more readily overcome barriers to accelerating the development and adoption of promising tools and technologies faced by either academia or industry working alone. The primary objective is to support milestone-driven, targeted technological development projects through strategic alliances and partnerships between academia and industry.
The partners are expected to establish a robust engineering solution and develop tools and technologies that fulfill an unmet need in biomedical research or the practice of medicine. The goal is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years.
Key Elements that set the BPI apart from the Parent R01 NOFO As written in the BPI PAR, there are several key elements that are required for this NOFO, including: A clear description of both Industrial and academic partners’ involvement and roles. A leadership plan that involves both industrial and academic partners. A set of specific milestones (quantitative when appropriate) and timeline.
A specific endpoint and deliverables within 5-10 years. Applicants planning to submit a BPI application with direct costs exceeding $500,000 in any one year are reminded that they must submit a white paper (see below) and seek written agreement from the NIBIB staff at least 6 weeks prior to the application receipt date.
Applicants are encouraged to contact the NIBIB staff well in advance of the 6-week deadline to discuss their planned application. NIBIB’s policy (that does not apply to NCI, NEI, NIA) is to only consider applications with a maximum budget of $600k/year for a maximum of 5 years.
If you are considering applying to the other participating institutes (NCI, NEI, NIA), please contact the contacts referenced at the bottom of this web page for any conditions that apply to their institute-specific funding policies.
BPI White Paper Budget Table Template (Excel Worksheet) Areas of high programmatic interest include: intelligent systems design and smart modeling enabling nanotechnologies for designed drug and gene delivery vehicles activatable imaging agents multiscale modeling in biomedical systems sensor and lab-on-a-chip devices for point-of-care testing development of engineered 3D human tissue model systems image-guided interventions in vivo microimaging of internal organs techniques for characterization and modification of biomaterial interfacial properties high-field and high speed (parallel) MRI high-frequency and very high-frequency ultrasound imaging and other applications novel sensing technologies enabling technologies for tissue engineering and regenerative medicine high-intensity focused ultrasound (HIFU) therapies or interventions computational analysis and simulation methods improvement of radiological diagnostics, image-guided therapies, and human health clinical decision-making support systems in-home treatment monitoring next-generation intelligent image and data analysis tools new technologies enabling direct imaging of targeted radio-therapies Bioengineering Partnership with Industry (U01 Clinical Trial Optional) PAR-24-325
Based on current listing details, eligibility includes: Research partnerships formed by academic and industrial investigators. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.